Compare Merck & Co., Inc. (MRK) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Merck & Co., Inc. trades at $146.2 (market cap $351.28B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.5 (market cap $72.20B). The key difference: Merck & Co., Inc. is far larger — about 4.9× Vanguard Intermediate Term Corporate Bond ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Vanguard Intermediate Term Corporate Bond ETF for 62 Days on average.
| MRK | VCIT | |
|---|---|---|
Market Cap | $351.28B | $72.20B |
Volume | 7,969,665 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $84.82 |
52-Week Low | $82.49 | $77.98 |
Typical Hold Time | 98 Days | 62 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $78.385, up 0.15% with a bearish technical signal from moving averages. The ETF maintains consistent $0.34 dividend payments and shows institutional interest with recent purchases by Engineers Gate Manager LP and HB Wealth Management. Technical indicators show mixed signals with RSI at neutral levels while ADX indicates strong trend momentum.
The ETF offers a compelling 4.8% yield with low 0.03% expense ratio, positioning it favorably against competitors. However, the bearish technical outlook and interest rate sensitivity present near-term risks. Long-term income investors may find value in VCIT's investment-grade corporate bond exposure despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
